Devonian Health Group Inc. reports developments as a clinical-stage biopharmaceutical company focused on therapies for fibro-inflammatory diseases. Company news centers on Thykamine™, including preclinical data in MASH and pulmonary fibrosis models, anti-inflammatory and anti-fibrotic research, intellectual-property filings, manufacturing controls and its radiodermatitis prevention program.
Recurring updates also cover Devonian's cosmeceutical activities, its Quebec extraction facility and Altius Healthcare Group LP, a commercialization subsidiary that sells licensed prescription pharmaceutical products in Canada. Corporate news includes financial results, board and management changes, shareholder meeting outcomes, stock-option grants and capital-structure actions such as its common-share consolidation.
Devonian Health Group Inc. has commenced quoting its shares on the OTCQB under the symbol DVHGF, while continuing its listing on the TSXv as GSD. This move enhances access to a broader range of U.S. investors and potentially improves liquidity and trading experience. The OTCQB is a reputable platform for early-stage companies, ensuring transparency and adherence to high financial standards. Additionally, eligibility for DTC facilitates easier trading and settlement, further supporting Devonian's strategic growth in the botanical pharmaceutical sector.